Back to Best of AC17 Session - Navigating New Treatment Paradigms in Relapsed or Refractory Multiple Myeloma
Best of AC17 Session - Navigating New Treatment Paradigms in Relapsed or Refractory Multiple Myeloma

Best of AC17 Session - Navigating New Treatment Paradigms in Relapsed or Refractory Multiple Myeloma

In 2015 the U.S. Food and Drug Administration (FDA) approved four new agents for the treatment of relapsed or refractory MM. In February, the FDA approved panobinostat (Farydak), the first histone deacetylase (HDAC) inhibitor to receive FDA approval. In November, the FDA accelerated the approval of daratumumab (Darzalex), the first-ever monoclonal antibody and immunotherapy for MM. In December, the second monoclonal antibody and immunotherapy option, elotuzumab (Empliciti), received FDA approval. Finally, ixazomib (Ninlaro), the fourth drug for MM and first oral proteasome inhibitor, was approved. In this session we will discuss the mechanism of action and adverse-event profile for each of these new agents.

 

Content Area: Patient Management & Therapeutics

Product Details

Session from the HOPA 2017 Annual Conference

Navigating New Treatment Paradigms in Relapse or Refractory Multiple Myeloma

Speaker: Houry Leblebjian, PharmD BCOP

Learning Objectives:

1.      Describe the new treatment options for multiple myeloma (MM) patients who have relapsed or are refractory to multiple lines of therapy.

2.      Discuss the mechanism of action and adverse-event profile of the new agents.

 

  • List Price: $35.00 USD
  • Member Price: $25.00 USD
Join and Save!
Log into see if you qualify for a lower price.
HOPA members save $10.00 USD or more!
Become a member